BeiGene
ONC
#734
Rank
ยฃ19.90 B
Marketcap
ยฃ171.29
Share price
-0.76%
Change (1 day)
61.89%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (ONC)

Earnings in 2024 (TTM): -ยฃ0.45 Billion

According to BeiGene 's latest financial reports the company's current earnings are ยฃ3.81 Billion. , an increase over its 2023 earnings that were of -ยฃ0.91 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 -ยฃ0.43 Billion-52.95%
2023 -ยฃ0.91 Billion-32.52%
2022 -ยฃ1.34 Billion24.39%
2021 -ยฃ1.08 Billion-13.21%
2020 -ยฃ1.24 Billion72.69%
2019 -ยฃ0.72 Billion36.01%
2018 -ยฃ0.53 Billion616.83%
2017 -ยฃ73.58 Million-15.24%
2016 -ยฃ86.81 Million107.91%
2015 -ยฃ41.76 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ13.57 Million-96.80%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ7.75 Million-98.18%๐Ÿ‡บ๐Ÿ‡ธ USA